Valo Therapeutics

Rank S100 index Change Change %   Business ID
366. (+4) 312 1 0.36 % 2768695-4

Founded: 2016 Category: Medical and Healthcare City: Helsinki

Valo Therapeutics (Valo Tx) is a developer of a novel cancer immunotherapy that is projected to transform the lives of millions of cancer patients. Our unique approach to immunotherapy in cancer, based on an oncolytic virus non-covalently combined with tumor-specific peptides, delivers a highly immunogenic and unique tumor vaccination platform. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of oncolytic virus and immunotherapy experts, who together with the founding scientist have the necessary expertise to take this patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing. The Business Concept: Valo Tx is positioned to transform the field of immunotherapy for a wide range of cancer types. Valo Tx's technology uniquely combines the best qualities of two distinct, proven cancer immunotherapy concepts - peptide vaccination and oncolytic virus-based immunotherapy. Valo Tx has developed a proprietary, genetically modified adenovirus that will form the basis of its therapeutic approach. Technology: Valo Tx’s methodology is to adsorb tumor-specific peptides to the surface of an oncolytic virus, thereby eliciting an enhanced adaptive immune response against tumors. The tumor-peptides are extended with a polylysine tail to increase their net charge so that the positively charged peptides bind to the negatively charged virus capsid. As opposed to genetically engineered changes to the virus, the Valo Tx technology facilitates the rapid creation of multiple virus-based immunotherapies that promises to provide lasting immunity to many different cancer types. This system addresses the need for tumor-specific and even personalized therapies, as the antigen expression varies in different patients and even in different stages of the same tumor.


News feed